NPS: Desvenlafaxine (Pristiq) not superior to venlafaxine for major depressive disorder

The National Prescribing Service Limited (Australia) made an independent evaluation on the role of desvenlafaxine (Pristiq) for the treatment of major depressive disorder. Summary: Desvenlafaxine is the active metabolite of venlafaxine. There is no evidence that desvenlafaxine is more effective, safer or better tolerated than venlafaxine or other antidepressants. Doses above 50 mg/day are unlikely […]

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos